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Abstract
Background Little is known about the perinatal aspects of COVID-19.
Objective To summarize available evidence and provide perinatologists/neonatologists with tools for managing their patients.
Methods Analysis of available literature on COVID-19 using Medline and Google scholar.
Results From scant data: vertical transmission from maternal infection during the third trimester probably does not occur or
likely it occurs very rarely. Consequences of COVID-19 infection among women during early pregnancy remain unknown.
We cannot conclude if pregnancy is a risk factor for more severe disease in women with COVID-19. Little is known about
disease severity in neonates, and from very few samples, the presence of SARS-CoV-2 has not been documented in human
milk. Links to websites of organizations with updated COVID-19 information are provided. Infographics summarize an
approach to the pregnant woman or neonate with suspected or confirmed COVID-19.
Conclusions As the pandemic continues, more data will be available that could lead to changes in current knowledge and
recommendations.
Introduction
In a near-prophetic study published in 2015, Menachery
et al. warned the medical and scientific communities of the
continued risk of the reemergence of severe acute respira-
tory syndrome coronavirus (SARS-CoV) from viruses cur-
rently circulating in Chinese bat populations [1]. In the
recent past, bat-borne viruses transmitted to humans have
led to human to human transmission, with high fatality
rates, as happened during the 2002–2003 SARS-CoV-1 [2]
and the 2012 Middle East Respiratory Syndrome Cor-
onavirus (MERS-CoV) [3] epidemics.
On November 17, 2019, the first case of infection with a
novel coronavirus was identified according to Chinese
government sources [4] and the World Health Organiza-
tion (WHO), which has maintained a day-to-day timeline
of the evolution of the current coronavirus pandemic. As
predicted by Menachery, through December 2019, spora-
dic cases in adults from the city of Wuhan, in the Hubei
province of China, developed severe respiratory symp-
toms. Initially, many patients had been exposed at the
Hunan wholesale seafood market, but even after closure of
this market on January 1, 2020, new cases continued to
present at an exponential rate, suggesting human to human
transmission [5, 6]. The outbreak was reported by China to
the WHO on December 31 and declared a pandemic by the
WHO on March 11, 2020 as many other countries
throughout the world reported new cases with high fatality
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rates [5]. These high rates may have been fueled by the
rapid propagation of the disease that proved country after
country, to rapidly exhaust reserve medical supplies and
the ability to provide intensive care to an overwhelming
increased numbers of patients [7]. The novel virus was
named SARS-CoV-2 and was identified as the agent of a
new respiratory syndrome named COVID-19.
Abundant research has been conducted to date in order to
better define the epidemiology, clinical characteristics,
prevention, and treatment of SARS-CoV-2 infection. Since
the first publications on COVID-19 appeared, a Medline
search conducted on March 18, using the keyword of
COVID-19 retrieved 1087 articles. Yet, very little is known
about the perinatal aspects of COVID-19.
The purpose of this Perspective is to summarize the
available evidence at this moment, and to provide perina-
tologists and neonatologists with practical tools for mana-
ging their patients, and offering links to reputable medical
organizations websites that are frequently updated. We
chose to address the following questions:
(1) Is there a vertical transmission of SARS-CoV-2
during pregnancy, and if so, can this lead to abortions,
premature labor, or congenital disease such as
observed in CMV or Zika disease?
(2) Is pregnancy a risk factor for severe COVID-19?
(3) What are the dangers of SARS-CoV-2 infection in
labor?
(4) What are the dangers of SARS-CoV-2 infection in
neonates?
(5) Can SARS-CoV-2 be transmitted through human
milk?
We will then describe current expert opinions/guidelines
of major organizations such as the United States Center for
Diseases Control (CDC), the American College of Obste-
tricians and Gynecologists (ACOG) and the Society for
Maternal–Fetal Medicine (SMFM), the United Kingdom
National Health Services (NHS), the Royal College of
Obstetricians and Gynecologists (RCOG), the Academy
of Breastfeeding Medicine (ABM), the National Institutes
of Health (NIH), and the American Academy of Pediatrics
(AAP).
Is there vertical transmission of SARS-CoV-2
during pregnancy?
Very few articles have attempted to answer this question.
The first was a retrospective review of nine Chinese preg-
nant women by Chen et al. with laboratory-confirmed
COVID-19 pneumonia [8]. All nine patients had a cesarean
section in the third trimester, but the indications for this
mode of delivery were not clearly stated. Amniotic fluid,
cord blood, and neonatal throat swabs all tested negative for
the virus.The authors of this small case series suggested that
there is currently no evidence for intrauterine infection
caused by vertical transmission in women who develop
COVID-19 pneumonia in late pregnancy. An additional
study published by Zhang in the Chinese language compared
16 pregnant women with COVID-19 to 45 women without
COVID-19 [9]. In this study, all infants in both groups were
delivered by cesarean section, at a gestational age of 38.7 ±
1.4 weeks in the COVID-19 group and 37.9 ± 1.6 weeks in
the control group. Only one of the 16 pregnant women with
COVID-19 had a severe disease. Ten neonates in the
COVID-19 group were tested by PCR and all were found to
be negative. Both studies, authored by Chen and Zhang
[8, 9], came from the same institution and it is not clear
whether or not there was an overlap among the patients. An
additional Chinese study by Fan et al. [10] described two
cases of COVID-19 during the third trimester of pregnancy,
which “failed to identify SARS-CoV-2 in all the products of
conception and the newborns”, and suggested a “low risk of
intrauterine infection by vertical transmission of SARS-
CoV-2”. An additional study by Chen et al. [11] reported
that three placentas from infected mothers tested negative for
the virus. Finally a most recent article by Chen et al.
described four infants delivered to mothers with COVID-19
during labor [12]. Infant testing was performed in only three,
who all tested negative for the virus. In an update [13],
authors of previous series described 33 neonates of whom 3
were reported to have early onset COVID-19 infection.
Nasopharyngeal/anal swabs for RT-PCR were not obtained
immediately after birth in any of the infants, indicating
positivity of the test does not prove vertical transmission.
There are only two reports in the nonmedical, general lit-
erature that suggested that vertical transmission may be
possible. In one report, an infant tested positive but testing
took place at 30 h of age when horizontal transmission
cannot be ruled out [14]. In contrast, in the second report, a
newborn with a positive test was born to a mother who was
also positive for the virus, and the newborn screening took
place “within a few minutes” after delivery [15]. This is
more suggestive of a vertical transmission. In a recent letter,
Dong et al report a newborn with elevated SARS-Cov-2
IgM, IgG and IL-16 levels at 2 hours after birth with
negative nasopharyngeal swabs for RT-PCR from 2 h to 16
d after birth; amniotic fluid, placenta, or cord blood was not
tested [16]. In an accompanying Editorial, Kimberlin and
Stagno caution interpretation of these results as confirmation
of vertical transmission due to a variety of concerns
including technical concerns with IgM assays [17]. Impor-
tantly, vertical transmission has not been observed in either
SARS-CoV-1 or in MERS-CoV [18]. From these scant data,
we cautiously conclude that vertical transmission from
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maternal infection during the third trimester probably does
not occur, or likely occurs very rarely. However, the con-
sequences of COVID-19 infection among women during
early pregnancy remain unknown. We do not know whether
the virus may be vertically transmitted to the fetus causing
malformations, fetal growth abnormalities, disruption of
maturing fetal organs, or leads to early fetal loss, abortions,
or induces premature onset of labor.
Is pregnancy a risk factor for severe SARS-
CoV-2 infection?
Pregnancy is a partially immunocompromised state and any
viral or bacterial pneumonia can be life-threatening during
pregnancy [19]. However, despite the fact that COVID-19
is known to cause severe life-threatening respiratory com-
plications in adults, especially the immunocompromised,
there are no comparative data to determine whether preg-
nancy is a risk factor for severe SARS-CoV-2 pneumonia.
In Chen’s study, all nine pregnant women had laboratory-
confirmed SARS-CoV-2. Eight of 9 women had evidence of
pneumonia on chest CT [8] and seven presented with fever.
Other symptoms included cough among 4 of 9 patients.
None of the patients died or developed severe SARS-CoV-2
pneumonia. Based on their small series of nine cases, the
authors concluded that the clinical characteristics of
COVID-19 pneumonia in pregnant women were similar to
those reported for nonpregnant adult patients. In the study
by Zhang et al. none of the 16 women with Covid-19
progressed to “critical pneumonia” [9]. Based on these scant
data, we cannot conclude if pregnancy is a risk factor for
more severe disease in women with COVID-19. It might be
important however to determine whether complications of
pregnancy such as diabetes, cardiac failure, or hypertension,
which have been identified as risk factors for severe
COVID-19 infections in nonpregnant adults, also represent
additional risk factors for pregnant women [20].
What are the dangers of COVID-19 infections
in labor?
In Chen’s study [8], all nine infants born to COVID-19
infected pregnant mothers had normal 1- and 5-min Apgar
scores. In Zhang’s study [9], the comparison of pregnancy
outcomes between 16 women with COVID-19 and 45
women without COVID-19 did not demonstrate any sig-
nificant differences in fetal distress, meconium-stained
amniotic fluid, preterm birth, and neonatal asphyxia.
These two small studies, with limited clinical information
lack clearly described indications for cesarean deliveries
and do not provide an answer to our question.
WHAT are the dangers of SARS-CoV-2
infections in neonates?
The report by Zhu et al. [21] represents a clinical ret-
rospective analysis of ten neonates born to nine mothers
with confirmed COVID-19 pneumonia. There were four
full-term infants and six were born prematurely; two
were small-for-gestational-age infants and one was
large-for-gestational-age (LGA). Six infants developed
RDS, two of them were febrile, and two had thrombo-
cytopenia with abnormal liver enzymes. Five infants
went home healthy, and when the article was published,
four were still hospitalized in stable condition, while one
child died. Specimens for SARS-CoV-2 analyses were
collected from nine of the ten neonates 1 to 9 days after
birth and all were negative. It is unclear if the compli-
cations noted were related to prematurity or to SARS-
CoV-2, but the negative testing would suggest that the
virus was unlikely to be the cause. In Dong’s report of
2143 children with Covid-19 in China, the illness
appeared to be most often less severe than in adults, as
only 13 patients were classified as “critical” [22]. In this
report, there were no infants classified as neonates, and
the youngest ones were classified as less than 1 year old.
From this report there is some suggestion that the
younger the child, the more severe the disease. In Chen’s
study [12], four full-term, singleton infants were born to
pregnant women who tested positive for COVID-19 in
the city of Wuhan where the disease was first identified.
None of the infants developed the typical COVID-19
symptoms of fever and cough, however two of them
developed rashes, one had facial ulcerations, and one
infant had respiratory distress which was supported by
noninvasive mechanical ventilation for 3 days. However,
none of the three infants out of four infants tested had
positive viral results and it is probable that the above-
mentioned symptoms were unrelated to SARS-CoV-2. In
their updated series of 33 infants, Zeng et al [13]
describe 3 infants diagnosed with pneumonia with per-
sisting positive viral detection by RT-PCR within a few
days of the first PCR; thus these 3 infants probably were
truly infected. Whether 2 of 3 term infants diagnosed
with pneumonia actually had pneumonia is unclear, as
they had no respiratory symptoms and their chest
radiographs lacked typical findings of pneumonia. The
third infant diagnosed as pneumonia, born prematurely
at 31 weeks, suffered from a depressed 5-minute Apgar
score, respiratory distress syndrome, and disseminated
intravascular coagulation. A blood culture yielded
Enterobacter agglomerans, suggesting symptomatology
was probably unrelated to SARS-CoV-2. Thus, we
cannot define from these limited data the extent of dis-
ease severity in neonates.
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Can SARS-CoV-2 be transmitted through
human milk?
In Chen H’s study of nine pregnant women with
laboratory-confirmed COVID-19 pneumonia, all breast
milk samples that were collected and tested from six
patients after the first lactation were negative for the virus
[6]. This is obviously an insufficient sample size to make a
definitive statement that SARS-CoV-2 is or is not excreted
in human milk.
Expert opinions/guidelines/useful links
(1) General prevention measures for preventing the
spread of infection:
We recommend using the CDC site for this
purpose. This website is regularly updated, and it is
not within the scope of this article to describe these
guidelines, which may be found at:
https://www.cdc.gov/coronavirus/2019-ncov/
infection-control/control-recommendations.html.
(2) Guidelines for inpatient obstetric healthcare settings:
these guidelines may be found at the website:
https://www.cdc.gov/coronavirus/2019-ncov/hcp/inpa
tient-obstetric-healthcare-guidance.html.
Briefly, pregnant patients who have confirmed
COVID-19 or who are “persons under investigation”
(PUIs) are instructed to notify the obstetric unit prior
to arrival in order to facilitate appropriate infection
control measures. The obstetric unit is to notify
infection control personnel in order to obtain appro-
priate guidance.
Infants born to mothers with confirmed COVID-19
should be considered PUIs and isolated as such.
After birth, in order to reduce the risk of
transmission of the virus from the mother to the
newborn, facilities should consider temporarily separ-
ating mother from her baby in a separate isolation
room until the mother’s transmission-based precau-
tions are discontinued. Visitors and staff members
should use appropriate PPE, including a gown, gloves,
facemask, and eye protection. Separation should be
discontinued on a case-by-case basis accounting for
disease severity, illness signs and symptoms, and
results of laboratory testing for the virus.
If rooming-in occurs in accordance with the
mother’s wishes or is unavoidable due to facility
limitations, the newborn should be kept ≥6 feet (~2 m)
away from his or her mother. Should the mother with
confirmed COVID-19 or PUI take care of her infant,
she should put on a facemask and practice hand
hygiene before each feeding or other close contact
with her newborn.
(3) Guidelines for breastfeeding.
These guidelines can be found at the website:
https://www.cdc.gov/coronavirus/2019-ncov/prepare/
pregnancy-breastfeeding.html.
Briefly: the CDC recommends that during tempor-
ary separation, mothers should be encouraged to
express their breast milk to establish and maintain
milk supply, using a dedicated breast pump, and after
adequate hand hygiene. This expressed breast milk is
intended may be fed to the newborn by a healthy
caregiver. As stated earlier, if a mother and newborn
do room-in and the mother wishes to feed at the breast,
she should put on a facemask and practice hand
hygiene before each feeding.
These CDC recommendations are consistent with
the ABM recommendations to be found in detail at the
website:
https://www.bfmed.org/abm-statement-coronavirus.
These are also the basis of the Society for
Maternal–Fetal Medicine guidelines to be found at
the website:
https://s3.amazonaws.com/cdn.smfm.org/media/
2267/COVID-19-_updated_3-17-20_PDF.pdf.
ACOG also adopted the CDC guidelines regarding
breastfeeding, as can be read in detail at the website:
https://www.acog.org/clinical/clinical-guidance/pra
ctice-advisory/articles/2020/03/novel-coronavirus-
2019.
(4) General advice for pregnant women who may have been
exposed to COVID-19 or are experiencing symptoms
suggestive of COVID-19. We suggest consulting the
UK NHS /RCOGguidelines which recommend that
pregnant women concerned about exposure or symp-
toms indicating possible infection with COVID-19
should not visit their GP practice or attend Emergency
Departments in person, but should rather contact their
local hotline and tell the operator of possible COVID-19
exposure, and self-isolate until advised otherwise.
More details are provided at the website:
https://www.rcog.org.uk/en/guidelines-research-
services/guidelines/coronavirus-pregnancy/covid-19-
virus-infection-and-pregnancy/.
(5) Advice regarding self-isolation for women with possible
or confirmed COVID-19
The above-mentioned NHS guidelines, like others,
recommend that pregnant women who have been
advised to be self-isolated, should stay indoors and
avoid contact with others for 14 days.
(6) The WHO has maintained a day-to-day tally of the
global and country-specific information concerning
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statistics and public health measures undertaken at
individual country levels.
https://www.who.int/emergencies/diseases/novel-
coronavirus-2019.
(7) The NIH has provided a quick access to the most recent
research on COVID-19 at the following address:
https://www.nih.gov/health-information/coronavirus.
This address allows registering to a mailing list of
participants that will receive automatic updates from the
NIH on Coronavirus.
(8) The AAP has built an educational website on COVID-
19, that may be reached at the following address: https://
services.aap.org/en/pages/2019-novel-coronavirus-
covid-19-infections/. Within this website, one can read a
document of “Initial Guidance” on the management of
infants born to mothers with COVID-19, published on
April 2, 2020, that may be downloaded from the
following address: https://download.aap.org/AAP/PDF/
COVID%2019%20Initial%Newborn%20Guidance.pdf.
This document is particularly useful as it describes the
personal protective equipment to be used and isolation
precautions to be taken, both for customary contact and
for high risk situations such as when patients require bag
and mask ventilation, intubation, tracheal suctioning, nasal
cannula oxygen at high flow, continuous positive airway
pressure and/or positive pressure ventilation of any type,
given the potential for these supports to generate aerosols.
It also provides preliminary guidelines for delivery room
management of neonates, instructions for newborn
admission after maternal separation, and guidance for
alternative well newborn care. The AAP recommends at
this point in time that molecular assay testing should be
done at approximately 24 hours of age in all infants born
to mothers with COVID-19, and that repeat testing should
be done at approximately 48 hours of age. The AAP
document also addresses the issue of maternal visitation
for infants requiring ongoing hospital care, and spells the
criteria that need to be met for visitation to happen.
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Conclusion
We strongly advise the readers that this Perspective be
considered preliminary. As the pandemic continues, there
will be more data available that could lead to significant
changes in the current recommendations. The above-
mentioned websites have been built by reputable organi-
zations and are updated frequently. They should establish
the best perinatal and neonatal practices. In the meanwhile,
we are providing an illustration (Fig. 1) that summarizes
many of the concepts described in this text. Figure 2 out-
lines a suggested algorithm for the perinatal and neonatal
management of a PUI (person under investigation) with
suspected COVID-19 infection.
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